ALB and cholangiocarcinoma: After removing patients who were diagnosed with fibrolamellar carcinoma and combined hepatocellular-cholangiocarcinoma, and who did not have intact clinical information (including age, height, weight, race, hepatitis B virus status, alcohol consumption, tumor grade, AJCC stage, APF level, platelet level, albumin level, Eastern Cooperative Oncology Group performance status (ECOG-PS) and sex), a total of 162 HCC patients with both intact genomic and clinical information were included for further analysis.